SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will participate in the following conferences in September:
- Citi’s 13th Annual Biotech Conference on Thursday, September 6, 2018 in Boston, MA. The Company will conduct one-on-one meetings with institutional investors at this conference.
- Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018, at 2:15 p.m. Eastern Time in New York, NY. The Company will participate in a fireside chat presentation at the conference, which will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.
Portola Pharmaceuticals, Inc.